Presenter Disclosure Information

1
Presenter Disclosure Information
The ASCOT Trial Morbidity and Mortality Outcomes From Lipid Lowering in a Hypertensive Patient Population. The following relationships exist related to this presentation The ASCOT Trial Morbidity and Mortality Outcomes From Lipid Lowering in a Hypertensive Patient Population. The following relationships exist related to this presentation The ASCOT Trial Morbidity and Mortality Outcomes From Lipid Lowering in a Hypertensive Patient Population. The following relationships exist related to this presentation
Name Research Grants Consultancies
Peter S. Sever Pfizer, Servier, AstraZeneca Pfizer, Servier, AstraZeneca
Björn Dahlöf Pfizer, Merck, AstraZeneca, Servier Pfizer, Merck, Boehringer
Neil R. Poulter Pfizer, Servier Pfizer, AstraZeneca, Merck/Schering Plough
Hans Wedel Pfizer, AstraZeneca Pfizer, AstraZeneca, Merck, Medtronic Inc
Gareth Beevers Merck
Mark Caulfield AstraZeneca
Rory Collins Merck, AstraZeneca
Sverre E. Kjeldsen Merck, AstraZeneca, Pfizer
Arni Kristinsson
Gordon T. McInnes Pfizer, Merck, Aventis, AstraZeneca AstraZeneca, Boehringer, Merck, Servier, Merck/Schering Plough
Jesper Mehlsen Pfizer Pfizer
Markku Nieminen Pfizer, Merck Pfizer, Merck, AstraZeneca
Eoin OBrien Pfizer, Servier
Jan Östergren Pfizer, AstraZeneca Aventis, Merck, AstraZeneca
2
P Sever (Co-chair), B Dahlöf (Co-chair), N
Poulter (Secretary), H Wedel (Statistician), G
Beevers, M Caulfield, R Collins, SE
Kjeldsen, A Kristinsson, J Mehlsen, G McInnes, M
Nieminen, E OBrien, J Östergren On behalf of
the ASCOT Investigators
3
The Anglo-Scandinavian CardiacOutcomes Trial
Randomised controlled trial of prevention of CHD
and other vascular events by blood pressure
lowering and by cholesterol lowering (factorial
design)
4
Rationale

• CHD incidence remains a major unresolved problem
  in BP management
• High prevalence of dyslipidaemia in hypertensive
  patients
• Combinations of risk factors synergistic for CHD
• No trial has specifically addressed benefits of
  lipid lowering in primary prevention of CHD in
  hypertensive patients not conventionally deemed
  dyslipidaemic

Sever PS, et al, for the ASCOT Investigators. J
Hypertens. 2001191139-1147
5

• The Anglo-Scandinavian Cardiac Outcomes Trial
  (ASCOT) is a multicentre, international trial,
  which involves 2 treatment comparisons in a
  factorial design
• A prospective, randomized, open, blinded end
  point (PROBE) design comparing 2
  antihypertensive regimens
• A double-blind, placebo-controlled trial of a
  lipid-lowering agent in a subsample of those
  hypertensive patients studied (lipid-lowering
  arm LLA)

Sever PS, et al, for the ASCOT Investigators. J
Hypertens. 2001191139-1147
6
Lipid-Lowering Arm (LLA)Primary Objective

• To compare the effects on the combined
  outcome of nonfatal MI (including silent MI) and
  fatal CHD of atorvastatin 10 mg with those of
  placebo in hypertensive patients with TC levels
  of ?6.5 mmol/L (?250 mg/dL)

7
Secondary and Tertiary End Points

• Secondary
• Primary outcome without silent MI
• All-cause mortality
• CV mortality
• Fatal nonfatal stroke
• Fatal nonfatal heart failure
• Total coronary end points
• All CV events and procedures

• Tertiary
• Silent MI
• Unstable angina
• Chronic stable angina
• Peripheral vascular disease
• Development of diabetes
• Development of renal impairment
• Major study end points in specific subpopulations

8
Sample Size and Statistical Power (LLA)
Primary End Point Nonfatal MI and Fatal CHD
Cholesterol reduction with statin 30 Relative
effect on end point of statin vs
placebo 30 Cumulative end point rate on placebo
for 5 years 6.35 Significance level 1
Power 90 Total sample size 9000
9
Patient Population LLA

• Eligibility criteria
• SBP ?160 mm Hg and/or DBP ?100 mm Hg (untreated)
  or SBP ?140 mm Hg and/or DBP ?90 mm Hg (treated)
• TC ?6.5 mmol/L (250 mg/dL) and TGs ?4.5 mmol/L
  (400 mg/dL)
• 40-79 years of age
• 3 CVD risk factors
• No history of CHD

10
ASCOT Study Design
R Randomized
18,000 patients
Sever PS, et al, for the ASCOT Investigators. J
Hypertens. 2001191139-1147
11
Therapeutic Interventions and Targets (LLA)

• Atorvastatin 10 mg vs placebo
• No fixed lipid-lowering target

12
Recruitment February 1998 May 2000

• 686 general practices in Denmark, Finland,
  Iceland,
• Norway, and Sweden
• 32 regional centres in Ireland and the UK

Total 10,305
13
Baseline Characteristics
Atorvastatin (n5168)
Placebo (n5137)
Characteristic
Age (years) Male () Caucasian () SBP (mm
Hg) DBP (mm Hg) TC (mmol/L mg/dL) LDL-C
(mmol/L mg/dL) TG (mmol/L mg/dL) HDL-C
(mmol/L mg/dL) Number of risk factors
63.1 8.5 81.1 94.6 164.2 17.7 95.0 10.3 5.5
0.8 (213 31) 3.4 0.7 (131 27) 1.7 0.9
(150 80) 1.3 0.4 (50 27) 3.7 0.9
63.2 8.6 81.3 94.7 164.2 18.0 95.0 10.3 5.5
0.8 (213 31) 3.4 0.7 (131 27) 1.6 0.9
(142 80) 1.3 0.4 (50 27) 3.7 0.9
Mean SD
14
ASCOT LLA Patient Population Risk Factor
Profile
All patients in ASCOT have hypertension plus ?3
risk factors for CHD
Patients with risk factor ()
Data on file
15

• The DSMB in September 2002 reported that in the
  lipid arm of ASCOT there was a highly significant
  reduction in the primary end point as well as a
  significant reduction in stroke
• The DSMB recommended that the double-blind
  cholesterol lowering study treatment arm be
  terminated since the results were outside of the
  stopping rules of the trial
• The Steering Committee endorsed the
  recommendation of the DSMB, and the lipid arm
  was closed after a median follow-up period of
  3.3 years

16
P Sever (Co-chair), B Dahlöf (Co-chair), N
Poulter (Secretary), H Wedel (Statistician), G
Beevers, M Caulfield, R Collins, SE
Kjeldsen, A Kristinsson, J Mehlsen, G McInnes, M
Nieminen, E OBrien, J Östergren On behalf of
the ASCOT Investigators
17
ASCOT LLA Patient Inclusion and Follow-Up Status
10,305 randomized in lipid-lowering arm
19,342 patients randomized to antihypertensive
treatment
212 dead with complete information
Complete information obtained on 98.8 of patients
18
ASCOT Statistical Methods

• Based on an Intention-to-Treat Analysis
• Time to first primary event
• Log-Rank Procedure and Coxs Proportional Hazards
  were used to calculate confidence intervals
• Cumulative Incidence Curves generated by using
  the Kaplan-Meier method

19
Blood Pressure Changes
Baseline 164/95 Treated 138/80
SBP (mm Hg)
LLA Close-out
DBP (mm Hg)
LLA Close-out
20
Reductions in Total and LDL Cholesterol
Atorvastatin 10 mg
Placebo
6
200
1.3 mmol/L
1.1 mmol/L
Total cholesterol (mmol/L)
(mg/dL)
150
4
100
2
0
1
2
3
150
4
125
(mg/dL)
3
LDL cholesterol (mmol/L)
1.2 mmol/L
1.0 mmol/L
100
2
75
1
LLA Close-out
0
1
2
3
Years
21
Primary End Point Nonfatal MI and Fatal CHD
Atorvastatin 10 mg Number of events 100 Placebo Nu
mber of events 154
36 reduction
HR 0.64 (0.50-0.83)
p0.0005
22
Secondary End Point Fatal and Nonfatal Stroke
Atorvastatin 10 mg Number of events
89 Placebo Number of events 121
27 reduction
HR 0.73 (0.56-0.96)
p0.0236
23
Secondary End Point All CV Events and Procedures
Atorvastatin 10 mg Number of events 389 Placebo Nu
mber of events 486
21 reduction
HR 0.79 (0.69-0.90)
p0.0005
24
Secondary Endpoint All Coronary Events
Atorvastatin 10 mg Number of events 178 Placebo Nu
mber of events 247
29 reduction
HR0.71 (0.59-0.86)
p0.0005
25
Secondary End Point All-Cause Mortality
Atorvastatin Placebo
Number of events 185 Number of events 212
HR0.87 (0.71-1.06)
p0.1649
26
End Points
Hazard Ratio 0.64 (0.50-0.83) 0.79
(0.69-0.90) 0.71 (0.59-0.86) 0.62
(0.47-0.81) 0.87 (0.71-1.06) 0.90
(0.66-1.23) 0.73 (0.56-0.96) 1.13 (0.73-1.78)
0.82 (0.40-1.66) 0.87 (0.49-1.57) 0.59
(0.38-0.90) 1.02 (0.66-1.57) 1.15
(0.91-1.44) 1.29 (0.76-2.19)
Risk Ratio
Primary End Points Nonfatal MI (incl silent)
fatal CHD Secondary End Points Total CV events
and procedures Total coronary events Nonfatal MI
(excl silent) fatal CHD All-cause
mortality Cardiovascular mortality Fatal and
nonfatal stroke Fatal and nonfatal heart
failure Tertiary End Points Silent MI Unstable
angina Chronic stable angina Peripheral arterial
disease Development of diabetes
mellitus Development of renal impairment
Atorvastatin better
Placebo better
0.5
1.0
1.5
Area of squares is proportional to the amount of
statistical information
27
Pre-specified Subgroups Primary End Point
Hazard Ratio
Risk Ratio
0.84 (0.55-1.29) 0.56 (0.41-0.77) 0.56
(0.37-0.85) 0.70 (0.51-0.96) 0.59
(0.39-0.90) 0.67 (0.49-0.92) 0.67
(0.35-1.29) 0.64 (0.49-0.84) 0.64
(0.47-0.86) 0.66 (0.41-1.06) 1.10
(0.57-2.12) 0.59 (0.44-0.77) 0.80
(0.45-1.42) 0.61 (0.46-0.81) 0.61
(0.44-0.84) 0.70 (0.47-1.04) 0.77
(0.52-1.12) 0.56 (0.40-0.79) 0.64 (0.50-0.83)
Diabetes Nondiabetes Current smoker Noncurrent
smoker Obese Nonobese LVH No LVH Older (gt60
years) Younger (60 years) Female Male Previous
vascular disease No previous vascular
disease Renal dysfunction No renal
dysfunction With metabolic syndrome Without
metabolic syndrome All patients
Atorvastatin better
Placebo better
0.5
1.0
1.5
Area of squares is proportional to the amount of
statistical information
28
Safety Evaluations

• Numbers of non-CV deaths were similar
  (111 atorvastatin, 130 placebo)
• No significant difference between atorvastatin
  and placebo in
• Incidence of fatal cancers
• Incidence of serious adverse events
• Incidence of liver enzyme abnormalities
• 1 nonfatal case of rhabdomyolysis in a patient
  receiving atorvastatin (causation confounded by
  alcohol abuse and recent febrile illness)

29
Summary and Conclusions

• In hypertensive patients at modest risk of
  CHD, and normal to moderately elevated
  cholesterol levels atorvastatin is associated
  with
• A highly significant reduction in the primary end
  point of CHD (36, p0.0005)
• Significant reductions in the secondary end
  points of stroke (27, p0.0236), all
  cardiovascular events and procedures (21,
  p0.0005), and total coronary events (29,
  p0.0005)
• These reductions in major cardiovascular events
  are large given the short follow-up time (median
  3.3 years) and occurred earlier than in many
  other statin trials
• There was no significant heterogeneity among
  pre-specified subgroups

30
Summary and Conclusions (continued)

• Risk reductions in CHD events were unrelated to
  baseline cholesterol levels
• Benefits occurred in the absence of any increased
  risk of non-cardiovascular disease, including
  fatal cancer
• These findings have implications for future
  lipid-lowering guidelines, particularly with
  reference to hypertensive patients

31
Sever PS, Dahlöf B, Poulter N, Wedel H, et al,
for the ASCOT Investigators. Lancet.
20033611149-58
32
Investigators

• Denmark EA Aabel, I Aagaard-Hansen, C Aasøe
  Rasmussen, JP Ærthøj, A Ajsik Aisen, S Andersen,
  I Andresen, A Arnesen, I Arnfred, A Baltsen, M
  Bang, L Bech Nielsen, J Bendsen, P Bendixen, S
  Bjerregaard, T Bjørnshave, P Bladt, K Borch, H
  Bork-Rasmussen, T Børresen, JM Brandt
  Wulff-Andersen, H Bro, K Brockelmann, J Brøndt
  Jørgensen, C Bryld, HH Carlsen, JS Christensen, M
  Christensen, O Christensen, N-E Damgaard
  Pedersen, T Damgaard Poulsen, A Drøhse, J Eisbo,
  A Engsig, JV Faaborg-Andersen, S Faurschou, TH
  Frederiksen, O Frimodt Olsen, BS Garne, P
  Glarbjerg Kraghede, T Gorlen, J Grølsted, J
  Günther, JK Gylling, R Hald Pedersen, LM
  Hallingskog, B Hecht-Hansen, S Hempel-Poulsen, O
  Hoffmann, M Holm, N Holmgaard Thomsen, N Hvass
  Hansen, PE Hven, A Jessen, JA Johannsen, J
  Jørgensen, PB Jørgensen, O Junge, P Kjærhus, M
  Kjærsgård, C Kjellerup, KR Kristiansen, J
  Kronsted Pedersen, P Kulmbach, NH Larsen, I
  Lassen Meyer, C Leerhøj Jørgensen, KM Lind, K
  Lindvig, K Lorentzen, HP Lund Thomsen, LE
  Lykkegaard, B Madsen, H Madsen, JA Madsen, J
  Magnussen, E Mathiassen, F Mathorne, O Melskens
  Mikkelsen, R Milling Eriksen, O Mogensen, K
  Mølenberg, B Møller, PC Møller, N Mosbæk, T
  Müller, H Mulvad, HB Nielsen, JC Nielsen, JE
  Nielsen, P Nielsen, H Nordentoft, KG Nyholm, M
  Ohrt, H Olesen, J Olesen, H Øllgaard, H Orsholt,
  E Ørum Schmidt, FT Østergaard, V Ottung, E Oxhøj,
  JB Parm, M Parm, JH Pedersen, M Perlt Hansen, HA
  Pescettini, JG Petersen, O Petersen, SE Poulsen,
  T Preisler, A Raft, HH Rasmussen, K Ravnbak, OB
  Riisgård Pedersen, FT Ritter-Petersen, SF Roed,
  NP Rothe Hansen, J Ruhwald, O Runesten, G Saaby
  Jensen, B Sand, O Sandgaard Pedersen, PJ Schultz,
  M Sie, B Sinding Steensberg, R Skjøth
  Christensen, B Skov Larsen, J Solgaard, P
  Søndergaard, J Søndergaard Jensen, KSM Sørensen,
  T Sørensen, NJ Stabel, K Svith Andersen, P
  Thoft-Christensen, J Thorup Pallesen, P Tiedemann
  Nyhuus, A Tvedegaard Pedersen, S Udholm, A
  Uhrenholt, B Varming, S Vejlø, H-J Vendelbo
  Knudsen, N Vesterheden, J Villadsen, UG
  Villadsen, S Vinter, S Vinther-Nielsen, F Vogel,
  B Vyberg, N Wickers Nielsen, N Wiinberg, S
  Winther Jensen, NJ Winther-Pedersen, A-G Wøldike,
  J Wøldike, C Wulff-Andersen, D Würtz.
• Iceland G Björgvinsson, B Gunnlaugsson, S
  Helgason, G Huld Blængsdóttiur, F Jóhannesdóttir,
  A Jóhannsdóttir, H Jónsson, H Kristjánsson, G
  Porkelsson, JB Ragnarsson, A Sigurdsson, H Thors,
  JB Thorsteinsson.
• Finland J Airas, K Ala-Kaila, R Antikainen, R
  Autio, K Azezian, S Bergkulla, M Blomqvist, M
  Cornu, M Ellonen, L Grönhagen, J Haapaniemi, V-M
  Häggman, T Hakamäki, V Hällberg, K Halonen, T
  Hälvä-Torday, H Hänninen, J Heinonen, T Heinonen,
  S Hellman, H Hentunen, P Himanen , A Hirvonen, M
  Hokkanen, H Honkanen, J Hopsu, H Huhtanen, P
  Hujanen, K Humaloja, M Hyvönen, R Icén, H
  Isotalus, E Jaakkola, M Jääskivi, V Järveläinen,
  J-P Jousimaa, S Junnila, L Juurinen, E Kähkönen,
  E Kaila, T Kaitila, R Kalli, T Kankaanpää, I
  Kantola, A Kaprio, T Karhi, M Karhu, A Karila, K
  Karjalainen, T Kärki, E Karonen, M Kastarinen, M
  Kekäläinen, S Kekki, T Knuth, P Kohonen-Jalonen,
  V Koivisto, O Konu, J Korhonen, K Korhonen, R
  Korhonen, H Kortesuo, P Kuusisto, E Kyllönen, T
  Larsio, A Latva-Nevala, E Lehmus, J Leppänen, S
  Majahalme, J Mäntymaa, M Mäntymaa, M Matintalo, P
  Matintalo, M Mattila, P Mattila, E Mattila, K
  Miettinen, J Muusavi, T Myllylä, R Nuuttila, M
  Nygård, K Nykopp, R Parviainen, M Pavela, T
  Pehkonen, L Penttinen, P Pihlaja, A Piiroinen, A
  Pinola, A Pohjamo, J Puhakka, K Puumala, R
  Puustinen, S Rajala, L Rantanen, J Rantonen, H
  Rasi, J Raustia, P Riikonen, M Rönty, E Rouhe, J
  Ruoppa, R Rytkönen, P Saarinki, T Saaristo, A
  Saarni, T Salkojärvi, M Salonius, P Saloranta, O
  Sammalkorpi, C Sarti, R Siren, T Smart, A
  Strandberg, S Sulosaari, T Tähtinen, S Tastula, P
  Tiitinen, O Tiitola, J Tolonen, P Uusimaa, M
  Vähätalo, T Valle, R Valovirta, J Valtonen, M
  Virtala, H Virtamo, H Wallinheimo, K Ylitolonen.
• Norway K Alme, TP Andersen, E Angell, R
  Apelseth, O Asskildt, BA Baastad, IT Bach-Gansmo,
  SE Barbo, JE Billington, IA Birkeland, J
  Bjorvand, PE Bø, B Bovim, B Bråtveit, P
  Brunovskis, OP Brunstad, B Brustad, J
  Christensen, S Crozier, E D'Angelo, J-E Davidsen,
  OR Drønen, T Eikeland, B-I Embrå, J Engh, M
  Eriksen, J Eriksson, T Erikstad, JK Fagernæs, J
  Fauske, B Folkvord, H Fonneløp, EA Fors, BE
  Fossdal, I Fossum, K Fossvik, TK Gaard, RE
  Gilhuus, J Giltvedt, K Gisholt, H Gjessing, KA
  Gråbø, M Grimsgaard, SA Grimstad, PC Gundersen, R
  Gundersen, TJ Gundersen, P-E Hafstad, SR Hagen, J
  Hammerstrøm, E Hånes, ÅN Hansen, PA Hansen, PE
  Hansen, T Hansen, AT Hansen-Krone, OI Håskjold, T
  Hatlebrekke, O Haug, BG Heggløv, K Heimdal, HJ
  Helgesen, H Helvig, P Hoff, PO Hognestad, T
  Holager, A Holm, R Holth, K Høye, TB Jacobsen, S
  Jensen, R Johansen, T-I Johansen, B Johnsen, T
  Johnsen, K Jonasmo, T Jøranli, AP Jørgensen, TA
  Jørstad, O Kaarby, A Kaisen, S Karlsen, S Karper,
  KO Kjørlaug, M Kleiven, R Kleiven, I Klepstad, CA
  Knutssøn, JC Krog, N-E Landmark, K-E Langaker, A
  Langhammer, BA Larsen, HB Larsen, EK Lein, NI
  Leraand, A Lerner, E Liljedal, JO Lindebø, C
  Loennecken, O Løland, T Lømsland, RA Løvøy, G
  Lund, KR Lund, D Lundgren, LJ Lysen, S Madsbu, P
  Madsen, SE Mårdh, K Mariadasan, J Markussen, JG
  Melby, TR Meling, JI Mikalsen, TA Mikkelsen, BT
  Moe, H Moen, K Mogen, KB Molteberg, P Myrstad, E
  Myrvang, S Nasrala, T Nilsen, B Nordang, D
  Nordvåg, J Nordvoll, B Norén, PD Norheim, M
  Nygård, ES Øfjord, T Ofstad, K Olsen, MH Olsen, O
  Olsen, V Opshaug, J Øvrebø, S Pedersen, AB
  Pettersen, C Platou, Ø Pløen, GA Råheim, Ø
  Rannestad, B Ravlo, S Reimer, S Reiten, R Rekve,
  V Rekve, N Ringdal, K Risberg, SO Rosenberg, SB
  Røsnes, LI Røssås, A Rygg, IK Rypdal, E Salen, H
  Sanaker, R Sannes, J Schelin, P Schrøder, AC
  Sellgren, GH Setekleiv, E Shetelig, SG Sivertsen,
  D Skaare, E Skjegstad, JC Slørdahl, JA Smith, SM
  Solberg, L Solnør, PA Stakkevold, TP Stavseng, R
  Steinum, HP Stokke, O Storrø, AM Strand, RO
  Strøm, M Svaland, HK Sveaas, A Svilaas, L
  Syltesæter, JO Syvertsen, M Tanem, T Taraldsen, T
  Teige, T Thomassen, O Thorsen, KO Thorsland, L
  Tjeldflaat, L-E Tobiasson, T Tomala, GJ Torød,
  POS Tøssebro, LE Traasdahl, J Tveit, H
  Tytlandsvik, Ø Vassel, SO Vedal, A Vedvik, OF
  Vego, P Vik, V Vollsæter, HM Wahl, K Wensaas, EL
  Werner, O Winge.
• Sweden P Ahlström, J Alvång, B Andersson, J-E
  Andersson, T Andersson, E Andersson, J Andersson,
  E Angesjö, K Antus, C Aurelius, O Bach Schmidt, B
  Bandh Henning, E Beling, T Bergholtz, E Berglund,
  O Berglund, JE Billner, M Björk, I Björkvald, A
  Blomberg, M Bood, G Boström, M Boström, R-M
  Brinkeborn, B-M Brogren, N Broman, S Bråthe, U
  Buuts, G Bülow, E Bylund, I Bäckström, B
  Carlborg, I Carlsson, P Cederquist, J Cettner, J
  Corin, O Cronberg, C Dahlin, A Dahlqvist, L
  Dotevall, A Egilsson, L Ehn, L Ejeklint, K
  Ekenbratt, R Ekesbo, B Eldeklint, A Elfstrand, B
  Eliasson, M Elm, M Engberg, J-O Engdahl, L
  Engquist, M Ericsson, U-B Ericsson, S Eriksson, A
  Eriksson, K Ermebrant, L Escuder Miquel, C
  Eskilson, B Fagher, K Fernström, M Flodin, K
  Fredlund, A Friman, M Frisk, L Fröberg, B
  Furunes, M Gaseb, A Gonn, K Grimstrup, CL
  Gustafsson, A Guterstam, K Gyllenhammar, C
  Hallendal, L Hallgren, B Hamborg, K Hammarlund, G
  Hedberg, M Hedlund, E Hefner, M Helenius
  Aronsson, I Hellberg, S Hellerstedt, P Hellman, N
  Henningsen, L Henningsson, A Henriksson, P Hertz,
  L Hjelmaeus, S Hofvendahl, B Hofverberg, S
  Hollenberg, U Hollertz, R Hollsten, J Holm, G
  Holmberg, L Hugmark, C Högberg, C Höglander, C
  Höglund, P Höök, B-M Iacobaeus, S Ingelög, B
  Isaksson, A Isaksson, B Isaxon, A Jacobsson, G
  Jacobsson Billfors, D Jerzewski, H Johansen, I
  Johansson, G Johansson, G Johansson, B Johansson,
  B Johnson, B Johnson, H Jones, P Jonsson, K Juul,
  C Jägrén, P Karlsson, M Karlstedt, I Karlström, P
  Katzman, A Kilström, L Klockhoff, A-C Knutsson, U
  Krigsman, L Kvist, I Lantz, H Larnefeldt, D
  Larsson, K Larsson, K Larsson, M Larsson, J
  Leinikka, C Liljenberg, G Lilliehöök, R
  Lindbergh, H-O Lindbergsson, B Linder, A Lindh,
  A-C Lindman, P Lindström, I Linnarsson, B
  Lorentzon, K Lund Larsen, I Lund Olsen, Å Lundén,
  W Lundgren, M Lundholm, T Lundmark, C Lütz, P
  Löfdahl, B Löfgren, L Lönneborg, G Madar, B
  Malmros, K Marcus, K Marits, B Martin, K
  Meischner, G Melin, T Morgardt, G Moser, J
  Munch, H Myhr, E Mägi, P Möller, C-M Mölstad, P
  Nicol, J Nielsen, B Nilsson, L Nilsson, K
  Nilsson, D Nilsson, IR Nilsson, I Nilsson, G
  Nilsson, L Nisbeth, D Norberg, L Norberg, J
  Nordberg, B Nordenhäll, T Nordlund, S Nordström,
  C Nordström, C Norinder, V Norlund-Elmroth, A
  Norring, L Norton, O Nybacka, L Nygaard-Pedersen,
  H-O Nylén, P Nyman, J Näsström, N Nörgaard, C
  Oldne, B Olerud, L Olofsson, A-M Olsen, L
  Paulsson, R Persson, O Persson, M Persson, R
  Peste, H Peterson, R Påhlsson, M Rados, H
  Rasmussen, B Reis, K Romberg, L Roos, M
  Rosengren, U Rosenqvist, G Roslin, P Rönmark, B
  Samuelsson, A Sandanam, R Schlüter, M Sedvall, U
  Siwersson, O Sjöberg, M Sjöberg, B Sjöberg, A
  Sjögren, P Skoghagen, J Skov, L Sohlström, A
  Spjuth, A Steen, K Stefferud, N Stenberg, E
  Stockenvall, S Strand, S Strid, B Sträng Olander,
  O Strömstedt, M Strömstedt, T Sturesson, D
  Sundberg, E Sundequist-Stockhaus, P Sundin, S-B
  Sundqvist, U Sundström, K Swantesson-Persson, J-O
  Svensson, E Svensson, L Särhammar, B Söderqvist,
  A Söderström, A Tenhunen, C Tevell, G Thingwall,
  G Thorbrand, T Thulin, M Tidén, C Tillberg, B
  Tilling, B Timby, L Tjäder, E Tjörnebo, K-E
  Tronner, H Unnegård, R Ustav, F Wagner, H-J
  Wagner, H Wahrenberg, B Walldén, J Wallmark, M
  Wargelius, G Vatnaland, H Wedegren, AC Weiderman,
  P Wendel, B Westerdahl, K Vetterskog, S Wide, G
  Widerström, M Widerström, M Widmark, L Wijkander,
  C Wikman-Lundbom, L Wikström, A Windling, P
  Vinnal, A Wirfält, N Wittmar, M Vlastos, G
  Wåström, S Zetterberg, E Zetterberg, R Zlatewa,
  MR Zucconi, H Åhlander, L Åkerman, K Åresund, P
  Östgård.
• UK and Ireland J Webster, C McNiff, J Furnace, A
  De Vries, H Clark, D Thomas, J Caldow, F Baxter,
  J Spreckley, G Cooper, N Smith, K Maclusky, J
  Aldegather, W Herring, M Maidment, J Golding, T
  Cockburn, C McCallum, M G Kirby, V Jenkinson, J
  Turner, J Reckless, R Howard, C Stirling, C
  Shute, G Beevers, G Lip, C Spencer, D Felmeden, R
  Watson, Z Townend, S Nadar, A Polmear, D Jenkins,
  J Timeyin, R Murray, R Vincent, N Morris, A
  Mackenzie, L Bennett, S Bassett, C Davidson, A
  Veiraiah, T Macdonald, N Tzemos, L Peebles, E
  Findlay, R Durrant, L Ross, J Anderson, C Hall, P
  Harikrishnan, G McInnes, J Wallace, A McLaughlin,
  M Wallace, B Williams, W Gamble, D OBrien, K
  Edwards, A Kirkham, S Basi, P Swales, P Lacy, J
  Harris, V Garratt, K Brown, S Sharma, J Robinson,
  K Jones, D Dev, J M James, H Parry, S Taylor, S
  Thomas, M Davies, H Forsyth, S Jones, K Barrass,
  M Mohteshamzsdeh, R Thanacody, L Cassidy, E Wray,
  N Wilkinson, LD Ritchie, B Strachan, H Gillespie,
  G Buchan, A Millward, E Malcolm, S Reily, C
  Meachin, A George. S Brown, M Salman, J Wise, M
  Wiltshire, D Davies, M Horne, H Shaw, M Thomson,
  E OBrien, A Stanton, H ONeill, D Fitzgerald, C
  Gribben, A Murphy, A Walsh, E Kinselle, A Hobb, C
  Wilson, S Sanmuganathan, M Twohill, J McGovern, N
  Moloney, D Farrell, G McCarthy, C Collier, L
  Hacke, B Aloul, G Glancey, T Heath, P OHare, V
  Patel, C Hill, G Tanner, K Mishra, K Webb, V
  Patel, R Nair, S Brown, C Moreton, P Jackson, E
  Wallis, C Green, J Day, M Taylor, J Yikona, W
  Yeo, R Williamson, P Sanmuganathan, C Nicholas, K
  Dobson, H Peel, K Cruickshank, M Holland, J
  Dunkerley, S Shaw, M Banerjee, M Hart, M Cullen,
  L Hardstaff, J Reynolds, D Collier, M Caulfield,
  C Wolff, S Wilson, D Dugboyle, L Cheesman, J
  Sheil, E Poulton, C Waleczko, R Rosenthal, S
  Richards, Z Wells, G Arunachalam, C David, E
  Dahler, G Salahi-Ali, G MacGregor, F Cappuccio, L
  Sullivan-Martin, C Carney, H Loomes, D Randall, T
  Antonios, P Swift, T Khong, N Markandu, R
  Kingston, S Thom, A Whitehouse, A McKerracher, J
  Macduff, S Leech, A Zambanini, R Fernandez, S
  Mitchell, L Kinsley, A Strain, O Tranor, Y Chim,
  M Liboro, D Robertson, C Verow, S Sumara, E
  Hughes, PK Banerjee, I Mohammed, RS Lawrence, PJC
  Cummin, RJ Barker, MT Lynch, A Ellis, C
  Shakespeare, E Ekpo, L Gogola, B Gordon, K
  Collins.